Lushang Freda Pharmaceutical Faces Valuation Challenges Amid Declining Sales and Profits

Lushang Freda Pharmaceutical Co., Ltd., operating within the realty sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, which are critical indicators of its market position and financial health. The stock's P/E ratio stands at 32, indicating a premium valuation compared to industry norms. Additionally, the Price to Book Value is recorded at 1.86, suggesting a higher market valuation relative to its book value. The EV to EBIT ratio is noted at 23.79, while the EV to EBITDA is at 15.50, both of which are significant metrics for assessing operational efficiency and profitability. Despite these valuation figures, the company has faced challenges, including a decline in net sales, which have contracted at an annual rate of -17.30% over the past five years. The operating profit has also shown a downward trend, decreasing at -12.77% during the same period. Furthermore, the latest financial results for September 2025 revealed the lowest net sales and operating profit figures, highlighting ongoing difficulties. Overall, the adjustment in evaluation for Lushang Freda Pharmaceutical Co., Ltd. underscores the complexities of its financial landscape and market dynamics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.